VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $5.75 price objective on the stock.

Separately, BTIG Research started coverage on shares of VYNE Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Stock Performance

Shares of VYNE Therapeutics stock opened at $2.58 on Tuesday. The stock has a 50 day moving average of $2.97 and a 200 day moving average of $2.35. The firm has a market capitalization of $38.06 million, a price-to-earnings ratio of -3.00 and a beta of 1.30. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.30.

Insider Transactions at VYNE Therapeutics

In other news, Director Patrick G. Lepore bought 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average price of $2.92 per share, with a total value of $43,800.00. Following the purchase, the director now owns 51,472 shares in the company, valued at approximately $150,298.24. The trade was a 41.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.80% of the company’s stock.

Institutional Trading of VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th largest holding. Lynx1 Capital Management LP owned approximately 0.11% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is owned by institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.